アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify (aripiprazole) oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia - acute treatment of manic and mixed episodes associated with bipolar i disorder - adjunctive treatment of major depressive disorder - irritability associated with autistic disorder - treatment of tourette's disorder abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhea

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - tolvaptan, quantity: 15 mg - tablet - excipient ingredients: hyprolose; magnesium stearate; microcrystalline cellulose; indigo carmine aluminium lake; lactose monohydrate; maize starch - samsca is indicated for the treatment of clinically significant hypervolemic or euvolemic hyponatremia (serum sodium less than 125 mmol/l, or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction) including patients with heart failure and syndrome of inappropriate antidiuretic hormone (siadh).

シンガポール - 英語 - HSA (Health Sciences Authority)

otsuka pharmaceuticals (singapore) pte. ltd. - tolvaptan - tablet - tolvaptan 15mg

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - decitabine, quantity: 35 mg; cedazuridine, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - inqovi 35/100 is indicated for the treatment of adult patients with myelodysplastic syndromes (mds) intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups, and patients with chronic myelomonocytic leukaemia (cmml).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - decitabine, quantity: 35 mg; cedazuridine, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - inqovi 35/100 is indicated for the treatment of adult patients with myelodysplastic syndromes (mds) intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups, and patients with chronic myelomonocytic leukaemia (cmml).

カナダ - 英語 - Health Canada

otsuka pharmaceutical co ltd - decitabine; cedazuridine - tablet - 35mg; 100mg - decitabine 35mg; cedazuridine 100mg - antineoplastic agents

カナダ - 英語 - Health Canada

otsuka pharmaceutical co ltd - decitabine - powder - 50mg - decitabine 50mg - antineoplastic agents

シンガポール - 英語 - HSA (Health Sciences Authority)

otsuka pharmaceuticals (singapore) pte. ltd. - aripiprazole - solution - aripiprazole 1.0 mg/ml

シンガポール - 英語 - HSA (Health Sciences Authority)

otsuka pharmaceuticals (singapore) pte. ltd. - aripiprazole - tablet - aripiprazole 2mg

マレーシア - 英語 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

luen wah medical co. sdn. bhd. - dextrose, anhydrous/anhydrous glucose -